key: cord-0809252-ff8tfehe
authors: Shiraki, Kimiyasu; Sato, Noriaki; Sakai, Kaoru; Matsumoto, Shirou; Kaszynski, Richard H.; Takemoto, Masaya
title: Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences
date: 2022-02-01
journal: Pharmacol Ther
DOI: 10.1016/j.pharmthera.2022.108121
sha: fbae080d32ebe92a3842e4697e5349c90c56c3eb
doc_id: 809252
cord_uid: ff8tfehe

Favipiravir, a broad-spectrum RNA-dependent RNA polymerase inhibitor, inhibits the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at significantly lower concentrations than the plasma trough levels achieved by the dosage adopted for influenza treatment and exhibits efficacy against coronavirus disease 2019 (COVID-19) pneumonia. Although high doses of favipiravir are required due to the molecule being a purine analog, its conversion into the active form in infected cells with active viral RNA synthesis enhances the antiviral specificity and selectivity as a chain terminator with lethal mutagenesis. Another characteristic feature is the lack of generation of favipiravir-resistant virus. COVID-19 pneumonia is caused by strong cell-mediated immunity against virus-infected cells, and the inflammatory response induced by adaptive immunity continues to peak for 3 to 5 days despite antiviral treatment. This has also been observed in herpes zoster (HZ) and cytomegalovirus (CMV) pneumonia. Inflammation due to an immune response may mask the effectiveness of favipiravir against COVID-19 pneumonia. Favipiravir significantly shortened the recovery time in patients with mild COVID-19 pneumonia by 3 days with the start of treatment by the 5th day of symptom onset. Since both CMV and COVID-19 pneumonia are caused by adaptive immunity and prevention of cytomegalovirus pneumonia is the standard treatment due to difficulties in treating refractory CMV pneumonia, COVID-19 pneumonia should be prevented with early treatment as well. In the present study, we have comprehensively reviewed the optimal antiviral therapy for COVID-19 based on clinical trials of favipiravir for the treatment of COVID-19 pneumonia and the concurrently established therapies for other viral infections, particularly HZ and CMV pneumonia. Optimally, antivirals should be administered immediately after COVID-19 diagnosis, similar to that after influenza diagnosis, to prevent COVID-19 pneumonia and complications resulting from microangiopathy.

The Coronavirus family affects the human respiratory system. The family includes severe acute respiratory syndrome (SARS) coronavirus, Middle East respiratory syndrome coronavirus, and the seventh novel coronavirus, which have caused a pandemic of severe pneumonia similar to SARS pneumonia (WHO, 2020c) . The causative virus has been named "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2) (ICTV, 2020) and the disease has been termed "coronavirus disease 2019" (WHO, 2020b) .

Immediately after the outbreak, Chinese researchers scanned more than 70,000 drugs or compounds through rigorous in silico simulations and in vitro enzyme activity tests and identified 5,000 potentially effective drug candidates. These drugs were then examined at the cellular level against the common coronavirus infection, and approximately 100 drugs were selected for further investigation. Among these drugs, chloroquine, favipiravir, and remdesivir were selected for testing in clinical trials (China, 2020; Wang, et al., 2020) . Favipiravir has been developed as an anti-influenza drug in collaboration with Toyama Chemical Co., Ltd., Japan (Furuta, et al., 2002; Shiraki & Daikoku, 2020) and has been shown to be therapeutically effective against COVID-19 pneumonia in several clinical trials (Cai, et al., 2020; Ivashchenko, et al., 2020; Shinkai, et al., 2021) .

We have previously reviewed the efficacy of favipiravir against influenza and Ebola virus infection (Shiraki & Daikoku, 2020) . Favipiravir is expected to play an important role as a therapeutic drug against COVID-19. Shiraki, who co-developed favipiravir, started his virology and antiviral research studies under the guidance of Professor Takahashi, who developed the Oka varicella vaccine (Takahashi, Otsuka, Okuno, Asano, & Yazaki, 1974) .

Varicella skin tests have been developed to evaluate adaptive cell-mediated immunity (CMI) against herpes zoster (HZ) (Shiraki, Yamanishi, & Takahashi, 1984; . Shiraki has conducted research on anti-herpes drugs such as acyclovir, famciclovir, ganciclovir, sorivudine, and amenamevir and analyzed their therapeutic efficacy in HZ (Shiraki, 2017 (Shiraki, , 2018 Shiraki, Takemoto, & Daikoku, 2021) . Both HZ and COVID-19 pneumonia show inflammation caused by adaptive CMI mediated by CD4 and CD8 lymphocytes and cytokines (Ackermann, et al., 2020; Morizane, Suzuki, Tsuji, Oono, & 

In the joint development of a new antiviral agent between the Shiraki laboratory and Toyama Chemical Co., Ltd. since 1992, approximately 30,000 compounds were synthesized.

Favipiravir (6-fluoro-3-hydroxy-2-pyrazinecarboxamide) was selected for its potent anti-influenza activity in tissue culture screenings at the Toyama Chemical Co., Ltd. The Shiraki laboratory investigated the efficacy of favipiravir in influenza-infected mice and ferrets in our Biosafety level 3 facility (Furuta, et al., 2002) . The control group died within 5 days of nasal infection with high-dose influenza virus, oseltamivir treatment extended survival by 3 days, and favipiravir treatment resulted in survival of all mice (K. . Thus, the efficacy of favipiravir in animal experiments served as the basis for clinical trials of the drug against seasonal influenza.

The efficacy of favipiravir against seasonal influenza was established through clinical trials in the United States and Japan. Based on these results, favipiravir was approved for the treatment of novel or re-emerging influenza in Japan in 2014. Moreover, favipiravir has proven to be effective for the treatment of patients with severe fever with thrombocytopenia syndrome and Ebola virus infection (Bai, et al., 2016; Sissoko D., 2016; Suemori, et al., 2021) . Favipiravir offers broad-spectrum anti-RNA virus activity, and its effectiveness in both animal and human trials has been shown in the literature (Delang, Abdelnabi, & Neyts, 2018; Furuta, et al., 2013; Furuta, et al., 2009; Shiraki & Daikoku, 2020) .

Favipiravir is a purine analog without ribose, unlike antiviral nucleoside analogs, and requires amidophosphoribosyltransferase action for the addition of phosphoribosylpyrophosphate to exhibit antiviral RNA-dependent RNA polymerase (RdRp) activity in its triphosphate form (Craig & Eakin, 2000) . Therefore, the dose of favipiravir required is higher than that of other antiviral nucleoside analogs. Favipiravir is specifically taken up and activated in RNA virus-infected cells with abundant RNA synthesis, which increases the specificity of anti-RNA virus activity of favipiravir.

7 ribonucleotide triphosphates (rNTPs) is added (Naydenova, et al. 2021 ).

A previous review discussed the lack of generation of favipiravir-resistant viruses (Shiraki & Daikoku, 2020) . Briefly, influenza virus and poliovirus were propagated in increasing concentrations of favipiravir for 1 month; however, favipiravir-resistant virus could not be isolated despite the presence of amino acid variations in the RdRp maintaining its enzyme activity and the susceptibility to favipiravir. This is unusual because the probability of generating favipiravir-resistant viruses under these conditions is high. Thus, favipiravir-resistant viruses have not become dominant among the entire virus population grown in the presence of favipiravir (Daikoku, et al., 2018; Daikoku, Yoshida, Okuda, & Shiraki, 2014; Goldhill, et al., 2018; Goldhill, et al., 2021) . Fifty-seven paired influenza viruses isolated from patients before and after favipiravir administration showed no change in susceptibility to favipiravir in a phase 3 clinical trial of seasonal influenza (Takashita, et al., 2016) . In contrast, acyclovir-resistant viruses have become dominant among the entire virus population grown in the presence of acyclovir in herpesvirus infections in vitro and in vivo (Akahoshi, et al., 2017; Daikoku, et al., 2018; Ida, et al., 1999; Shiraki, Ogino, Yamanishi, & Takahashi, 1983 ).

Viral RNA produced in influenza-infected cells is recognized by Toll-like receptor (TLR)-3 or TLR-7/8, which induces various cytokines, such as interleukin (IL)-1 and 6, tumor necrosis factor (TNF)-α, and interferons (IFNs) (Guillot, et al., 2005; Kurokawa, Brown, Since early embryonic deaths and teratogenicity have been observed in viral RdRp inhibitor animal studies, favipiravir and ribavirin should not be administered to pregnant or possibly pregnant women. Ribavirin has anti-RNA viral activity and has been used for the treatment of parainfluenza virus infections (Sidwell, et al., 1975) , respiratory syncytial virus infection (Krilov, 2002) , and chronic hepatitis C (Awad, et al., 2010) . The Ribavirin Pregnancy Registry has prospectively reported 464 pregnant women exposed to ribavirin, and preliminary findings do not suggest clear signs of human teratogenicity (Sinclair, et al., 2017) .

Ribavirin induced congenital abnormalities of the limbs, ribs, eyes, and central nervous system as well as fetal death when administered to pregnant hamsters (Kilham & Ferm, 1977) . Ribavirin inhibits both DNA and RNA synthesis and has an increased risk of causing malformation in fetuses compared to cytosine arabinoside (Kochhar, 1990 ).

Shiraki and Toyama Chemical Co. Ltd. compared early embryo lethality and teratogenicity in animals treated with antivirals. Ribavirin inhibits both RNA and DNA synthesis, whereas favipiravir selectively inhibits RNA synthesis. Toxicity studies were performed based on the area under the curve (AUC) in the "early embryogenesis" and "embryo-fetal development" tests. Favipiravir and ribavirin increased post-implantation mortality and reduced the number of living embryo/fetuses at lower rat/human AUC ratios (Table 1) . Ribavirin showed fetal anomalies at lower rat/human AUC ratios (Table 2) .

In contrast to valacyclovir, favipiravir and ribavirin were more toxic in early embryogenesis than in the embryo-fetal development stage (Tables 1 and 2 ). Since telomerase reverse transcriptase (TERT) expression is a characteristic event during early embryogenesis, the possibility of TERT-mediated disorders has been examined in the literatures.

Telomeres protect the ends of chromosomes with repetitive sequences and shorten the lagging strand by 50-150 bases during each cell division until termination by gradual loss of telomeric sequences, called senescence (Hayflick & Moorhead, 1961; Olovnikov, 1973 (Fig. 1B) . However, the infected cells (brown) in the center completed viral DNA synthesis within 12 h and, therefore, are resistant to acyclovir with high EC 50 values and are not eliminated. These cells continue to produce viral proteins and particles ( Fig. 1A and B) and are the target of immune responses and augment inflammation after initiation of antiviral therapy until they become apparently normal.

VZV and HSV cause eruptions and vesicles on the skin through adaptive CMI;

however, the skin becomes apparently normal over time with no erosions or ulcers due to extensive cell necrosis. Despite showing strong cytolytic activity in cell cultures, VZV-infected cells became apparently normal morphology with losing antigen expression but retaining viral DNA by antigenic modulation (Joseph & Oldstone, 1975; Shiraki, et al., 2011) .

Erythema multiforme occurs 1-3 weeks after recovery of HSV skin lesions, and HSV DNA is detected in the cells of erythema multiforme lesions (Miura, Smith, Burnett, & Aurelian, 1992) . The infected cells in HSV lesions are converted to apparently normal cells, leaving HSV genome in the cells until development of erythema multiforme. Nasopharyngeal epithelial cells are infected with influenza virus, but they neither die nor generate erosion in the nasopharyngeal mucosa and revert to normal epithelial cells during recovery.

VZV, HSV, and influenza virus-infected cells die in culture, but they survive without leaving skin or mucous membrane defects, returning to apparently normal cells in the skin and mucosa. The infected cells with antigen expression after peak of virus production become targets of adaptive CMI and stimulate the immune system for a few days until they revert to normal cells without viral antigen expression.

immunity by sunburn enables viral spread and replication in the prodromal phase, and adaptive CMI against HSV and VZV results in broader, denser, and more severe skin lesions called "photodistribution" (Fig. 2 ) (Gilchrest & Baden, 1974) . Innate immunity suppresses viral replication and spread in the prodrome. Adaptive CMI generates eruptions and vesicles on areas of HSV and VZV replication, known as delayed-type hypersensitivity (DTH), through T cell responses, including CD4 and CD8 lymphocytes (Morizane, et al., 2005) .

Severely immunocompromised patients, such as children with leukemia who lack CMI, either have a longer incubation period of 3-4 weeks or do not present with skin rashes throughout the course of varicella, indicating that skin lesions are caused by adaptive CMI. VZV spreads more widely in immunocompromised patients and some older people than in healthy patients due to the longer incubation period, resulting in a wide range of severe HZ manifestations (Dworkin, et al., 2007) . Photodistribution shows the significance of suppressing viral spread and growth by innate immunity in the prodrome, and the severity of skin lesions is determined by the extent of viral infection before the onset of adaptive CMI.

Typical adaptive inflammation caused by DTH is known as a type IV hypersensitivity reaction presenting as the positive tuberculin test, contact dermatitis, and urushiol-induced dermatitis. Inflammation presents as redness and swelling within 5-6 h in a limited area, increases in size and peaks during 48-72 h, and takes a week to disappear. As inflammation due to DTH peaks 3 days after contact with the antigen, inflammation in HZ exacerbates 3-5 days after onset due to continuous stimulation and augmentation by infected cells and lasts for 3 weeks (Fig. 3 ). Fig. 4 shows the pathophysiology and timing of initiation of established antiviral treatment for influenza, varicella and HZ, recurrent herpes, and CMV pneumonia. Since innate immunity suppresses viral growth and spread in the prodrome and determines the severity of infection, the efficacy of antiviral therapy can be determined by the inhibition of virus growth in the prodrome. Information on antiviral therapies can help understand the optimal therapy for COVID-19.

Vigorous replication of influenza virus induces cytokine production mediated by TLR-3, J o u r n a l P r e -p r o o f Journal Pre-proof in the upper respiratory tract, resulting in influenza-specific symptoms such as fever, sore throat, nasal discharge, and myalgia, which appear within 1-2 days of infection (Betakova, Kostrabova, Lachova, & Turianova, 2017; Y. Gu, et al., 2019; Kurokawa, et al., 1996; Tsurita, et al., 2001) . Seasonal influenza has an incubation period of 1-2 days, and the symptoms resolve after 3-7 days in uncomplicated influenza (Carrat, et al., 2008; Memoli, et al., 2014) . Preexisting immunity to seasonal influenza viruses is crucial to decrease the susceptibility and severity of seasonal influenza (Doyle, et al., 1994) .

Influenza virus replicates in the nasopharyngeal epithelium. The infected epithelial cells survive and continue to produce viral RNA and antigens until they revert to healthy epithelial cells without epithelial defects. Oseltamivir shortens the duration and severity of influenza symptoms, but the symptoms continue for 1 day after treatment (Treanor, et al., 2000) .

continues until the mucosal epithelium reverts to normal.

Influenza is treated with anti-influenza drugs within 48 h of the onset of the innate immune response, and the duration of treatment is 5 days. A single dose of baloxavir marboxil, laninamivir, and peramivir is recommended for treatment of influenza ( Fig. 4A ) (CDC, 2021b).

Varicella induces CMI against viral replication in the skin and internal organs during the 2-week incubation period and causes papules, vesicles, and crusts due to adaptive CMI (Asano, et al., 1993; Grose, 1981; Ku, Besser, Abendroth, Grose, & Arvin, 2005) .

Treatment for varicella is initiated within 24 h of onset and continues for 5-7 days ( Fig. 4B) , and some eruptions do not progress to vesiculation (abortive infection). Seven-day therapeutics are very effective in preventing the appearance of new rashes and the spread of existing rashes, but they cannot alleviate inflammation. Anti-herpetic drugs accelerate viral clearance, prevent new rash formation, decreases pain, and cause disappearance of crusting.

However, these drugs do not significantly accelerate rash healing (Balfour, et al., 1983; Kawashima, et al., 2017) . Inflammatory conditions of skin lesions, indicated by redness, swelling, and vesiculation, worsen during 3-5 days, regardless of initiation of anti-herpetic drug treatment, indicating the ineffectiveness of antivirals in alleviating inflammation (Fig. 3) .

Although the combination of acyclovir and prednisolone accelerated rash healing and pain reduction in HZ, it could not decrease the time taken for the complete healing of conditions associated with more adverse events (Wood, et al., 1994) . Anti-herpetic drugs in combination with prednisolone are generally reserved for complicated HZ, such as Ramsay Hunt syndrome, to alleviate inflammation (Albrecht, 2020) .

Anti-inflammatory steroids reduce inflammation caused by urushiol-induced or contact dermatitis without shortening the duration of inflammation. Similarly, antiviral drugs against HZ prevent the appearance of new skin lesions and inhibit the progression to vesiculation without reducing the duration or inflammation, even with the use of prednisolone (Balfour, et al., 1983; Wood, et al., 1988) .

HSV causes recurrent orofacial and genital lesions that typically occur within 1 week ( Fig. 4C ). Prodrugs offer simplified twice-a-day dosing (Patel, et al., 2015; Patel, et al., 2017) .

Oral anti-herpetic drugs initiated within 24 h of onset and continued for a period of 5 days are effective in reducing the severity and duration of recurrent lesions by a median of 1-2 days.

Short-course therapies of 1-3 days have shown similar efficacy. Initiation of treatment in the prodrome created by innate immunity is effective in preventing the appearance of genital lesions in approximately one-third of patients. Thus, prodromal treatment improves patient quality of life without vesiculation or ulcers in the face or genitalia.

ganciclovir treatment for ≥3 weeks, pneumonia was occasionally exacerbated even after treatment initiation. Thus, CMV pneumonia treatment was changed to CMV pneumonia prophylactic treatment. Guidelines have been established to initiate prophylactic treatment with ganciclovir or letermovir, when CMV DNAemia or antigenemia is observed (Chemaly, et al., 2014; Ljungman, et al., 2019; Razonable & Humar, 2019) . The introduction of these standard procedures eliminates the risk of refractory CMV pneumonia in transplant recipients ( Fig. 4D ). Prevention has become the standard treatment for CMV pneumonia. This experience can be used for the COVID-19 treatment strategy from treatment to prevention of COVID-19 pneumonia and microangiopathy.

Seasonal influenza causes symptoms such as fever because cytokines and interferons, produced by innate immunity, suppress the growth of the virus and aid in resolution of the infection (Fig. 4A ). The overall incidence of oseltamivir-resistant virus infection was 10 of 182 (5.5%) and 9 of 50 (18%), in two previous studies, after five days of oseltamivir treatment among children (Kiso, et al., 2004; Whitley, et al., 2001) . The emergence of baloxavir-resistant mutants occurred in 2.2% and 9.7% of baloxavir recipients in phase 2 and phase 3 trials, respectively (Hayden, et al., 2018) . Resistant viruses appear during antiviral therapy. In contrast, no virus exhibited reduced susceptibility to favipiravir in 57 pairs of influenza viruses in phase 3 clinical trials (Takashita, et al., 2016) . Virus secretion continues and may be accompanied by pneumonia in immunocompromised patients.

In HSV and VZV infections, the virus rapidly proliferates and spreads during prodrome, and the adaptive CMI forms skin lesions and resolves ( Fig. 4B and C). Antiviral drugs are administered for 5-7 days, starting from the appearance of skin lesions in the late prodrome and beginning of adaptive CMI. In immunocompromised patients, chronic skin lesions with viral replication persist despite the use of antiviral drugs due to the lack of sufficient CMI to eliminate the virus. Therefore, if skin lesions in a patient with immunodeficiency do not improve after 2 weeks of antiviral therapy due to persistent viral growth, the emergence of drug-resistant strains should be considered (Shiraki, et al., 2021) . frequent in isolates from patients naïve to acyclovir than in those who experienced episodic or suppressive therapy, when examined as viral clones (Daikoku, et al., 2016) . The virus strain in chronic active viral lesions in immunocompromised hosts is replaced with resistant strains, and lesions do not improve and gradually spread during antiviral treatment. It has been reported that chronic lesions are improved by antiviral drugs with different mechanisms of action (Onaka, Shiraki, & Yonezawa, 2021; Shiraki, et al., 2021) .

An optimal window to initiate antiviral therapy in influenza, varicella, HZ, recurrent herpes, and CMV pneumonia has been established, as shown in Fig. 4 . When antiviral treatment is initiated in the prodrome of the innate immunity phase of varicella, recurrent herpes, and CMV pneumonia, treatment effectively prevents the onset of major symptoms. COVID-19 pneumonia is caused by adaptive CMI, including CD4 and CD8 lymphocytes, with a strong inflammatory cytokine response (Ackermann, et al., 2020; Frisoni, et al., 2021; Song, et al., 2020) . The time interval after infection and infiltrated cellular response indicate that COVID-19 pneumonia is caused by adaptive CMI, similar to the major symptoms of HSV, VZV, and CMV infections.

The prodromal stage of innate immunity alleviates major symptoms; is a crucial stage that determines severity of infection, as shown by photodistribution; and is the optimal time for antiviral therapy. Varicella can be prevented by initiating antiviral therapy in the prodrome, and in recurrent herpes, antiviral drugs in the prodrome can prevent the formation of blisters. CMV pneumonia can be prevented by prophylactic or preemptive treatment.

In Ebola virus-infected mice, all mice who received favipiravir treatment from 6 days after infection survived, but those who received treatment from 8 days after infection died (Oestereich, et al., 2014) . A 2-day delay is fatal for lethal infections. Favipiravir successfully prevented Ebola virus transmission when administered immediately after percutaneous needlestick exposure (Jacobs, et al., 2015) . The use of anti-human immunodeficiency virus J o u r n a l P r e -p r o o f Journal Pre-proof drugs and hepatitis B immunoglobulins immediately after percutaneous exposure to human immunodeficiency virus and hepatitis B virus, respectively, is a standard practice to prevent infection (Marrazzo, et al., 2014; Puro, et al., 2005) .

Antiviral therapy for COVID-19 should start with fever caused by innate immunity and blocks the viral spread and damage to the epithelial cells, the airway, endothelial cells, and nerve cells for smell and taste, indicating that optimal COVID-19 therapy is prevention of pneumonia and microangiopathy and not treatment of pneumonia, as shown in Fig. 5 .

SARS-CoV-2, an enveloped positive-sense RNA virus, infects cells via the angiotensin-converting enzyme 2 receptor, and the viral spike protein is a key target for viral neutralization (P. Zhou, et al., 2020) . The incubation period of SARS-CoV-2 is approximately 2-14 days, and the median incubation period is 4-6 days, with 5%-10% of individuals developing symptoms after ≥14 days of exposure (Backer, Klinkenberg, & Wallinga, 2020; Bi, et al., 2020; Li, et al., 2020) . Presymptomatic transmission of SARS-CoV-2 occurs 1-3 days before onset (Cheng, et al., 2020; Wei, et al., 2020; WHO, 2020a) . The presence of underlying diseases, including hypertension, diabetes mellitus, cardiovascular diseases, chronic pulmonary diseases, obesity, and malignancy, and age > 60 years has been identified as risk factors for severe illness (ChinaCDC, 2020; Stokes, et al., 2020) .

Fever and cough are the most common symptoms in hospitalized patients. Loss of smell and taste was observed in 1,754 (73.1%) and 1,136 (60.5%) patients, respectively, among 2,013 European patients (Lechien, et al., 2020) . Fever, cough, loss of smell and taste, and malaise are the initial symptoms associated with COVID-19. The relatively high frequency of anosmia and ageusia may help distinguish COVID-19 from other acute febrile illnesses.

COVID-19 causes cardiovascular and nervous system complications and coagulation abnormalities in addition to pneumonia (Bhatnagar, et al., 2021) . Autopsy findings in fatal COVID-19 have revealed wide dissemination of the virus in the brain, heart, kidneys, and other organs, indicating that SARS-CoV-2 causes infection outside the pulmonary system (Bhatnagar, et al., 2021; Puelles, et al., 2020) . Arrhythmias and other cardiovascular symptoms are associated with electrocardiographic abnormalities, myocarditis, ischemia, and cardiomyopathy (Abrams, et al., 2020; Madjid, Safavi-Naeini, Solomon, & Vardeny, 2020) .

The most frequent neurological manifestations in a previous study were myalgia (44.8%), headache (37.7%), encephalopathy (31.8%), dizziness (29.7%), dysgeusia (15.9%), and anosmia (11.4%) (Liotta, et al., 2020) . Nervous system symptoms in patients with severe infection results in acute cerebrovascular diseases, impaired consciousness, and skeletal muscle injury (Mao, et al., 2020) . Thromboembolic complications cause pulmonary embolism during pneumonia and stroke in patients with underlying diseases (S. X. Gu, et al., 2021; Merkler, et al., 2020) . Thus, COVID-19 may lead to systemic complications involving the pulmonary, cardiovascular, and nervous systems as well as sensory disorders (Ellul, et al., 2020; Rogers, et al., 2020; Zubair, et al., 2020) .

Most children infected with SARS-CoV-2 consistently present a milder course and have better outcomes than adults worldwide. During the initial 3 months of the pandemic Viner, et al., 2021) . Moreover, the incidence rate of clinical symptoms of fever, cough, or shortness of breath during COVID-19 was lower in children than in adults (73% vs. 93%). Further, the rates of hospitalization and ICU admission was estimated to be 5.7%-20% and 0.58%-2.0%, respectively (Bialek, et al., 2020) . Concomitant medical issues ranging from rash to severe

Kawasaki-like disease have been sporadically reported in Western countries, but there are few such reports in Eastern countries (Verdoni, et al., 2020) . COVID-19 is milder in children than in adults, and although the reason is unclear, the expression and function of the angiotensin-converting enzyme 2 and immune response are speculated to play important roles (Bunyavanich, Do, & Vicencio, 2020; Felsenstein & Hedrich, 2020; Williams, et al., 2020) .

COVID-19 pneumonia appears after 4-6 days and dyspnea on day 8 of onset caused by adaptive CMI (Ackermann, et al., 2020; Frisoni, et al., 2021; Huang, et al., 2020; Song, et al., 2020) . The pathological pattern of lung injury in COVID-19 pneumonia appears to be similar to that in SARS or Middle East respiratory syndrome pneumonia . (Table 5 ) (Ackermann, et al., 2020; Bhatnagar, et al., 2021) . T-cell infiltration is more prevalent in COVID-19 pneumonia than in influenza pneumonia, indicating the involvement of a more potent CMI that causes inflammation. Increased levels of IL-6, IL-10, and C-X-C motif chemokine ligand 10; lymphopenia (decreased CD4+ and CD8+ T cells); and decreased IFN-γ expression (in CD4+ T cells) are also associated with severe COVID-19 (Laing, et al., 2020; Pedersen & Ho, 2020; Song, et al., 2020) . with mild and 28 (27%) with severe symptoms at the end of the observation period (Inui, et al., 2020; Tabata, et al., 2020) . Asymptomatic pneumonia cases showed a greater proportion of ground-glass opacity to consolidation (83%), while symptomatic cases more frequently showed a greater proportion of consolidation to ground-glass opacity (41%). Fig. 6 shows a pulmonary image of a 73-year-old patient with asymptomatic pneumonia. Pneumonia and alveolar microangiopathy in some patients may progress inconspicuously without dyspnea despite underlying hypoxia at PaO2 <60 mmHg and PaCO2 >39 mmHg (range, 41-49 mmHg), a condition referred to as "Happy hypoxia," resulting in poor prognosis (Couzin-Frankel, 2020; Tobin, Laghi, & Jubran, 2020).

The emergence and rapid spread of SARS-CoV-2 variants of the spike protein is a J o u r n a l P r e -p r o o f grave concern for COVID-19 vaccine efficacy, with some variants being more infectious and contagious than earlier forms of the virus (CDC, 2021d; Rambaut, et al., 2020 Rambaut, et al., , 2021 WHO, 2021c) . Variants are divided into three categories-variants of interest, variants of concern (VOC), and variants of high consequence (CDC, 2021d; WHO, 2021c) . VOCs show an increase in transmissibility, more severe disease, significant reduction in neutralization by antibodies generated during previous infection or vaccination, and reduced efficacy of vaccines (CDC, 2021a; Hacisuleyman, et al., 2021; WHO, 2021b) .

The variants have adapted to humans, acquired tropism to the airway epithelium, and spread faster and broader in the airway than the prototype (Bhatnagar, et al., 2021; Hou, et al., 2020; Laporte, et al., 2021; Volz, et al., 2021) . Since the variants spread broader in the respiratory tract than the prototype during the incubation period of pneumonia from infection, the range of pneumonia expands broader in the variant-infected area in the respiratory tract than in the prototype-infected area. As mentioned in Section 3.2., pneumonia caused by variants is first found in a limited area, and inflammation spreads in the infected area of the lung in 3-5 days, resulting in severe pneumonia. VZV infection in immunocompromised individuals spreads widely with a long incubation period before CMI and causes widespread severe lesions and pneumonia, as described in Section 3.2, and variants spread widely even in healthy individuals.

The dosage regimen of favipiravir is twice-daily oral administration of 1600 mg on day 1, followed by 600 mg for 4 days in adults to maintain favipiravir blood concentration between 240 and 380 µM for influenza treatment (PMDA, 2014) . A similar regimen is recommended for patients with severe fever with thrombocytopenia syndrome, with a loading dose of 1800 mg twice a day on day 1, followed by 800 mg twice a day for 7-14 days (Suemori, et al., 2021) .

Coronaviruses have the largest genome, with approximately 30 kb, among all RNA viruses, and SARS coronavirus has an enzyme with proofreading function (Smith, Blanc, Surdel, Vignuzzi, & Denison, 2013) . The susceptibility of SARS-CoV-2 to favipiravir is indicated by an EC 50 of 61.88 μM , μM in the viral replication inhibition assay, respectively (Shannon, et al., 2020) . These values are lower than the trough value of favipiravir in influenza (Fig. 7) , and the maintenance of J o u r n a l P r e -p r o o f anti-SARS-CoV-2 concentration suggests its efficacy in COVID-19. Direct inhibition of SARS-CoV-2 replication in endothelial cells prevents microangiopathy in the nervous, cardiovascular, and pulmonary systems (Ackermann, et al., 2020; Aid, et al., 2020; Bhatnagar, et al., 2021; S. X. Gu, et al., 2021; Thacker, et al., 2021) . The advantage of drug repositioning is the availability of information on the drug's efficacy, side effects, and pharmacokinetics.

Based on the results of in vitro studies, the efficacy of favipiravir has been demonstrated in hamsters infected with SARS-CoV-2 and in human clinical trials (Cai, et al., 2020; Kaptein, et al., 2020; Shinkai, et al., 2021) .

Favipiravir and acyclovir, which are competitive inhibitors of guanosine triphosphate, have been assessed using the plaque reduction assay because the yield reduction assay is not suitable for competitive inhibitors of nucleosides. Multiplicity of infection at 0.001 and >1

plaque-forming unit per cell is used in the plaque reduction assay and the yield reduction assay, respectively. Since the ratio of the guanosine analog to viral RNA/DNA should theoretically have similar inhibitory ratios between the two assays to show similar antiviral activity, approximately 100-1000-fold higher concentrations of favipiravir or acyclovir are required in the yield reduction assay than in the plaque reduction assay (Shiraki, et al., 1992; Sleeman, et al., 2010; Yajima, et al., 2017) . The EC 50 values of remdesivir, lopinavir, chloroquine, umifenovir, berberine, cyclosporine A, and molnupiravir against SARS-CoV-2 have been reported to be 0.77-0.99, 5.2, 1.13 -1.38, 3.5, 10.6, 3, and 3.4 μM, respectively (Cox, Wolf, & Plemper, 2021; Pizzorno, et al., 2020; Wang, et al., 2020) . Although the EC 50 of favipiravir is higher than that of other repurposed drugs because of the nucleoside precursor, favipiravir is expected to show efficacy at the same dose as that in Ebola virus infection (Bai, et al., 2016; Jacobs, et al., 2015; Sissoko, et al., 2016) .

We have reported the structural and sequencing analysis of poliovirus and revealed that favipiravir binds to the active site of its RNA polymerase and the lack of generation of favipiravir-resistant mutants (Daikoku, et al., 2018) . RNA synthesized in the presence of favipiravir is elongated and favipiravir causes mutation in viral genome in favipiravir-treated cells despite chain termination in various viruses (Arias, Thorne, & Goodfellow, 2014; Baranovich, et al., 2013; Delang, et al., 2014; Goldhill, et al., 2019; Shannon, et al., 2020; Vanderlinden, et al., 2016) . A similar study has investigated the interaction between favipiravir and SARS-CoV-2 (Naydenova, et al., 2021; Peng, et al., 2021; Shannon, et al., 2020) .

Structural studies have revealed the structure of the nsp12-nsp7-nsp8 core polymerase complex of SARS-CoV-2 with FTP. They have shown that the nonproductive binding mode of FTP to the catalytic site of SARS-CoV-2 RdRp and little covalent incorporation, making a covalent bondage with the adjacent nucleotide, into the replicating strand result in an inefficient rate of incorporation in primer extension assays, and short RNA is produced due to chain termination (Naydenova, et al., 2021; Peng, et al., 2021) . When the effect of favipiravir on RNA synthesis was analyzed biochemically in various viruses, chain termination was detected and short RNA strands were formed in primer extension assays (Jin 

In an open-label non-randomized control study, patients were assigned to either the favipiravir and IFN-α inhalation group (n = 35) or lopinavir/ritonavir and IFN-α inhalation group (n = 45) (Cai, et al., 2020) . A significantly shorter viral clearance time was observed in the favipiravir group (day 4) than in the lopinavir/ritonavir group (day 11, P < 0.001). The incidence improvement rate according to the chest image was not significant on day 9; however, it significantly increased by day 14, with 91.43% in the favipiravir group and 62.22% in the lopinavir/ritonavir group (P = 0.004).

An interim report of an adaptive multicenter, open-label, randomized, phase II/III clinical trial of favipiravir (Avifavir ® ) versus the standard of care (SOC) in hospitalized patients with moderate COVID-19 pneumonia has been reported (Ivashchenko, et al., 2020) . 

In a randomized, placebo-controlled, single-blind comparative study conducted in Japan, the time to viral clearance and symptom relief (body temperature, oxygen saturation, and chest image) was examined in 156 patients with non-severe COVID-19 pneumonia (Shinkai, et al., 2021) . Favipiravir significantly shortened the time to symptom relief from 14.7 days for placebo to 11.9 days (P = 0.0136); the adjusted hazard ratio was 1.593 (95% confidence interval 1.024-2.479). As shown in Fig. 8 , COVID-19, unlike HZ, is a 3-week illness that combines 5-6 days of viral replication, followed by an inflammation period, due to adaptive immunity of approximately 2 weeks. The shortened time to symptom relief by 2.8 days with favipiravir treatment is defined by shortening of the viral replication period; since one cycle of viral replication is approximately 10 h, shortening of 2.8 days corresponds to the inhibition of 6 viral replication cycles (Shiraki & Kobayashi, 2020) . Therefore, favipiravir is expected to show a similar therapeutic potential in COVID-19 to that of an anti-herpetic drug in HZ.

confirming the efficacy of Avifavir ® (favipiravir)

A multicenter, open-label post-marketing clinical study on the efficacy of favipiravir was conducted in 940 hospitalized patients with moderate-to-severe and severe COVID-19, including 470 patients in the favipiravir and standard of supportive care (control) groups (Corritori, et al., 2021; Viriom-Inc, 2021) . The median duration of onset was 4.9 days for the favipiravir group and 4.7 days for the control group. The median time to virus elimination in the favipiravir and control groups was 8 and 12 days, respectively (P < 0.001). The median time to clinical improvement in the favipiravir and control groups was 12 and 15 days, respectively (P < 0.001), with a significantly greater number of patients showing clinical improvement in the favipiravir group than in the control group at 7 days (P = 0.0248) and 14 days (P < 0.001). The favipiravir group showed statistically significant improvement compared to the control group, with 33% faster virological response, 20% shorter time to normalization of clinical symptoms, and 31% lower mortality rate.

Many clinical studies on favipiravir treatment for COVID-19 pneumonia have been conducted after the onset of pneumonia, but not before the onset of pneumonia, and this is not an optimal time for initiating treatment for viral infections, as mentioned in Section 4.

According to clinical studies, favipiravir administration within 4 days of onset is more desirable that after 4 days of onset (Fujii, et al., 2021; Hassanipour, et al., 2021) , but clinical trials initiating treatment approximately 5 days after onset still showed efficacy in patients with COVID-19 pneumonia (Cai, et al., 2020; Ivashchenko, et al., 2021; Shinkai, et al., 2021) .

Due to the similarities between COVID-19 pneumonia and HZ in viral replication and inflammatory patterns, antiviral treatment inhibits viral RNA/DNA synthesis, but it does not improve immune-induced inflammation of pneumonia and skin lesions. Although favipiravir has been shown to be effective in the treatment of pneumonia, experience in treating CMV pneumonia indicates the need to initiate treatment early or at least when pneumonia can be prevented.

COVID-19 causes influenza-like symptoms due to innate immunity, and pneumonia is caused by adaptive CMI. As discussed in Section 4, antiviral treatment should be initiated at the optimal window during the prodromal phase of influenza-like fever, where innate immunity suppresses the growth and spread of viral infections. The optimal treatment of J o u r n a l P r e -p r o o f Journal Pre-proof COVID-19 with favipiravir requires early treatment immediately after diagnosis, similar to that in acute viral infections of influenza and varicella.

Kidney transplant recipients and patients with chronic renal disease are at a high risk of developing critical COVID-19 due to chronic immunosuppression and comorbidities (Cravedi, et al., 2020; Gansevoort & Hilbrands, 2020) . A solid organ transplant recipient with chronic kidney disease tested positive on the PCR test on day 2 of fever, and oxygen saturation decreased on day 3 along with high fever, lymphocytopenia, and a high C-reactive protein level. After initiating favipiravir treatment on day 3, oxygen saturation recovered on day 4, the fever disappeared on day 5, and the PCR test result was negative on day 6 (Sakai, et al., 2020) . A high-risk patient was diagnosed with COVID-19 shortly after the onset of fever, and favipiravir treatment improved symptoms, similar to that in influenza, and severe pneumonia and complications were avoided.

In vivo, and oral molnupiravir within 5 days of onset has been shown to reduce the risk of hospitalization or death by approximately 50% compared to the placebo in patients with mild or moderate COVID-19 in a phase 3 study (Fischer, et al., 2021; Merck & Co., 2021; Rosenke, et al., 2021; Wahl, et al., 2021) .

AT527, an anti-viral RdRp drug, has exhibited anti-SARS CoV-2 activity both in vitro and in vivo (Good, et al., 2021) , and clinical trials have been conducted in patients with onset ≤5 days (NCT04709835 and jRCT2031210070).

Moreover, 3CL protease (MPro), a cysteine endoprotease, cleaves coronavirus polyprotein into active viral proteins, resulting in the formation of infectious viruses.

Masitinib is a 3CL protease inhibitor that inhibits the processing of polyprotein and replication of SARS CoV-2 in vitro and in vivo (Drayman, et al., 2021) , and its clinical trial has been conducted in patients with symptomatic mild-to-moderate COVID-19 with onset ≤5 days (NCT05047783,). A clinical trial of the 3CL protease inhibitor S-217622 developed in Japan has been conducted in patients with symptomatic mild-to-moderate COVID-19 with onset ≤5 days (jRCT2031210350).

PF-07321332/Ritonavir (PAXLOVID ® ) has shown 89 % efficacy by administration 1-3 days after onset (NCT04960202) (Pfizer Inc.). Ritonavir is an antiretroviral drug and may help the increase and maintain PF-07321332 concentrations in patients by inhibiting the cytochrome P-450 CYP3A4 enzyme, which degrades the second protease inhibitor, PF-07321332 (Zeldin & Petruschke, 2004) .

The efficacy of COVID-19 vaccines has been reported in 95% vaccine recipients, whereas 5% have been reported to have mild infection (FDA, 2020a (FDA, , 2020b . Promotion of COVID-19

vaccines will end the acute phase of the COVID-19 pandemic (CDC, 2021c; WHO, 2021a).

The neutralizing antibody titer achieved by COVID-19 vaccines is higher than that in convalescent patients, and booster immunization is planned to maintain the antibody titer . However, COVID-19 vaccines induce neutralizing antibodies and CMI to the spike protein, but they cannot produce mucosal antibodies that are important for infection protection. Therefore, breakthrough infection is unavoidable because mucosal 

Favipiravir needs to be administered at a high therapeutic dose due to it being a purine and not a nucleoside analogue, but its conversion to the active form in infected cells with active RNA synthesis enhances the specificity and selectivity of antiviral action. Favipiravir has shown promising therapeutic efficacy against COVID-19 pneumonia. This review describes the optimal time for antiviral COVID-19 treatment based on the experiences of antiviral therapy for influenza, varicella, HZ, recurrent herpes, and CMV pneumonia and many clinical studies on favipiravir for the treatment of COVID-19 pneumonia. Current antiviral therapy, initiating from the prodromal stage by innate immunity, is essential for the prevention and alleviation of the main symptoms of infection. As the major symptoms of viral infections are caused by adaptive CMI, immunosuppressants and anti-cytokine antibodies are more effective than antiviral drugs in alleviating major inflammatory symptoms.

The most efficacious treatment of COVID-19 pneumonia was found to be similar to the treatment strategy for CMV pneumonia, i.e., prevention instead of treatment. Clinical trials for COVID-19 treatment have shown that antiviral therapy should be initiated within 3 days after symptom onset and during the prodromal stage to achieve maximum effectiveness-this is similar to other viral infection as stated in Section 4.

Regardless of the widespread use of vaccines, antiviral therapy for COVID-19 is required in case of vaccine failure, reinfection, or variant infection. Optimal treatment with Table 1 Summary of toxicity of favipiravir and antiviral drugs for early rat embryogenesis −, numerical data were not presented since the dose of 60 mg/kg was applied in another study.

Statistically significant difference from the vehicle control: *, p<0.05; **, p<0.01.

The J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f Table 4   Table 5 Adverse events associated with favipiravir in Fujita Health University (Doi, et al., 2020) (n=7) Table is created from the report (Ackermann, et al., 2020) . Infected cells in the center died in culture, but they do not cause tissue loss or defects due to death and reverse to apparently normal cells in the skin of patients with herpes zoster.

The infected cells colored in yellow in the periphery will not produce viral proteins, and those colored beige and brown in the center are resistant to acyclovir and produce viral proteins and particles until they reverse to apparently normal cells regardless of the presence of acyclovir.

These beige and brown-colored infected cells are the major targets of CMI that causes inflammation.

Coronavirus-infected cells produce cytokines, such as interleukin (IL)-1, IL-6, IL-8, individuals were prophylactically treated with acyclovir during the first and second halves of the incubation period, and infection was confirmed by increase in antibody level (Suga, Yoshikawa, Ozaki, & Asano, 1993) . Prophylactic acyclovir administration during the second half of the incubation period including the prodrome was effective in converting chickenpox infection to asymptomatic infection. C. Recurrent herpes (Patel, et al., 2015; Patel, et al., 2017) : Episodic treatment shortens the disease course duration by a median of 1-2 days, making short course therapy with prodrugs sufficient. Treatment during the prodromal stage leads to an abortive infection that does not cause herpetic lesions in the one-third of patients, avoiding the occurrence of unpleasant lesions and symptoms that stay for a week. Suppressive Optimal treatment for COVID-19. Antiviral treatment should be started in the prodromal phase, which is produced by innate immunity, fever, or influenza like symptoms to block the spread of the virus into the respiratory tract, endothelium, and neurons, resulting in preventing pneumonia and other complications. (NIID) of Japan, respectively (Ohashi, et al., 2020; Wang, et al., 2020) . The plasma concentrations of favipiravir were higher than the EC 90 and 3 × EC 50 values for SARS-CoV-2 throughout the day, suggesting the therapeutic potential of favipiravir against COVID-19

infection. 1800 mg/800 mg BID： loading dose of 1800 mg twice a day followed by 800 mg twice a day for six days. 1600 mg/600 mg BID: loading dose of 1600 mg twice a day followed by 600 mg twice a day for six days. 

Ultraviolet light depletes surface markers of Langerhans cells

Clinical and cardiac characteristics of COVID-19 mortalities in a diverse New York City Cohort

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques

Acyclovir-resistant herpes simplex virus 1 infection early after allogeneic hematopoietic stem cell transplantation with T-cell depletion

Treatment of herpes zoster in the immunocompetent host

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Favipiravir elicits antiviral mutagenesis during virus replication in vivo

The mystery of the pandemic's 'happy hypoxia

Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets

Purine phosphoribosyltransferases

COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium

Characterization of susceptibility variants of poliovirus grown in the presence of favipiravir

Subclinical generation of acyclovir-resistant herpes simplex virus with mutation of homopolymeric guanosine strings during acyclovir therapy

Characterization of susceptibility variants of influenza virus grown in the presence of T-705

SARS-CoV-2 causes severe epithelial inflammation and barrier dysfunction

Favipiravir as a potential countermeasure Nasal and otologic effects of experimental influenza A virus infection

Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2

Neurological associations of COVID-19

Moderna COVID-19 Vaccine

Pfizer-BioNTech COVID-19 Vaccine

SARS-CoV-2 infections in children and young people

Molnupiravir, an Oral Antiviral Treatment for COVID-19. medRxiV

Cytokine storm and histopathological findings in 60 cases of COVID-19-related death: from viral load research to immunohistochemical quantification of major players IL-1beta, IL-6, IL-15 and TNF-alpha

AVIGAN Tablets 200mg package insert

Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients

Infection of human alveolar macrophages by human coronavirus strain 229E

Photodistribution of viral exanthems

Determining the Mutation Bias of Favipiravir in Influenza Virus Using Next-Generation Sequencing

The mechanism of resistance to favipiravir in influenza

Favipiravir-resistant influenza A virus shows potential for transmission

AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19

Variation on a theme by Fenner: the pathogenesis of chickenpox

Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation

Role of the Innate Cytokine Storm Induced by the Influenza A Virus

The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials

Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents

The serial cultivation of human diploid cell strains

Seminal fluid ribavirin level and functional semen parameters in patients with chronic hepatitis C on antiviral combination therapy

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Naming the 2019 Coronavirus

Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir-resistant variants

Chest CT Findings in Cases from the Cruise Ship "Diamond Princess

AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

COVID-19

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients

Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the

European Conference on Infections in Leukaemia

Potential Effects of Coronaviruses on the Cardiovascular System: A Review

An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

HIV prevention in clinical care settings: 2014 recommendations of the lnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-c ompared-to-placebo-for-patients

Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza

Detection of viral DNA within skin of healed recurrent herpes simplex infection and erythema multiforme lesions

The role of CD4 and CD8 cytotoxic T lymphocytes in the formation of viral vesicles

Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP

Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model

Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment

Suppression of generation and replication of acyclovir-resistant herpes simplex virus by a sensitive virus

A theory of marginotomy. The incomplete copying of template national guideline for the management of anogenital herpes

European guidelines for the management of genital herpes

SARS-CoV-2: a storm is raging

Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir

Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study

Towards avigan approval for Coronavirus infection (COVID-19)

Comparison of antiviral assay methods using cell-free and cell-associated varicella-zoster virus

Isolation of drug resistant mutants of varicella-zoster virus: cross resistance of acyclovir resistant mutants with phosphonoacetic acid and bromodeoxyuridine

Emergence of varicella-zoster virus resistance to acyclovir: epidemiology, prevention, and treatment

Viral ribonucleotide reductase attenuates the anti-herpes activity of acyclovir in contrast to amenamevir

Biologic and immunologic characterization of the soluble skin-test antigen of varicella-zoster virus

In vitro and in vivo effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) on types 1 and 3 parainfulenza virus infections

The Ribavirin Pregnancy Registry: An Interim Analysis of Potential Teratogenicity at the Mid-Point of Enrollment

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses

Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics

Immunological and inflammatory profiles in mild and severe cases of COVID-19

Coronavirus Disease 2019 Case Surveillance -United States

A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome

Effect of oral acyclovir against primary and secondary viraemia in incubation period of varicella

Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis

In vitro and in vivo activities of T-705 and oseltamivir against influenza virus

Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay

Live vaccine used to

Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults: A Systematic Review and Meta-analysis

Viriom and Chromis publish results of a multi-center open label post-marketing clinical study in 940 COVID-19 patients confirming efficacy of Avifavir at CROI2021

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Presymptomatic Transmission of SARS-CoV-2 -Singapore

Oral oseltamivir treatment of influenza in children

Global surveillance for COVID-19 caused by human infection with COVID-19 virus

SARS-CoV-2 in children: spectrum of disease, transmission and immunopathological underpinnings

A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster

Efficacy of oral acyclovir treatment of acute herpes zoster

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor

Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients

Mechanism of action of favipiravir against SARS-CoV-2: Mutagenesis or chain termination? Innovation (N Y)

A pneumonia outbreak associated with a new coronavirus of probable bat origin

beta-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells

Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review

We appreciate Drs. Motoko Yanagita, Osamu Kobayashi, Yasushi Okuno, Tetsuo Nakayama, and Vimolmas Lipipun for helpful comments, Drs. Shinichiro Yasumoto and Nozomu Toyama for providing the photographs of HSV infection and varicella, and herpes zoster lesions,